BioMarin Pharmaceutical Hits 52-Week Low at USD 51.56 Amid Decline

BioMarin Pharmaceutical, Inc. has reached a new 52-week low, trading at USD 51.56 on October 14, 2025. This marks a significant decline for the small-cap company, which has seen its stock price decrease by 36.74% over the past year, contrasting sharply with the S&P 500's performance of 14.44% during the same period.
The company's market capitalization stands at approximately USD 10.83 billion, reflecting its position within the pharmaceuticals and biotechnology industry. BioMarin's price-to-earnings (P/E) ratio is currently at 20.00, indicating how the market values its earnings relative to its stock price. Additionally, the company has a price-to-book ratio of 1.80, suggesting a moderate valuation compared to its net assets.

Despite the recent price movement, BioMarin maintains a return on equity of 11.84%, showcasing its ability to generate profit from shareholders' equity. The company does not offer a dividend, and its debt-to-equity ratio is reported at -0.14, indicating a unique financial structure. As BioMarin navigates these market conditions, its performance metrics will be closely monitored by stakeholders.